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Background: Multivessel and LM lesions, CTO are the indications
of CABG. But currently, it is possible to do PTCA in patients with
coronary ischemia, even after CABG
Methods: 3 years data was analysed in post CABG patients. Details
of CABG, current disease and CAG were noted. PTCA was done
with DES or BMS. Patients were followed up on OPD basis
Results: There were 24 post CABG patients who underwent
attempted PTCA. Mean time of presentation after CABG was 8.6
years. Mean age was 56.63 years. 13 (54.16%) were male,
11(45.88%) were female. DM, HTN, dyslipidemia were present in
14(54.33%), 17(70.83%), 16(66.66%) respectively. Avg LVEF was
40.68%.
Presentation at the time of CABG was CSA, STEMI, NSTEMI, USA
in 3(12.5%), 8 (33.33%), 7(29.16%), 6(25%) respectively and presen-
tation at the time of PTCA was 12(50%), 2(8.33%), 4(16.66%), 6(25%)
respectively
During CABG, 24(100%) had LIMA to LAD graft. SVG graft was
used for RCA, LCX, RCA and LCX in 8(20.83%), 5(12.5%), 10(54.33%)
respectively. 1 (8.33%) had RIMA to RCA graft.
During CAG, total and subtotal occlusion was present in
6(33.33%) and 5(27.77%) patients in LAD, 5(27.77%) and 4(22.22%)
patients in RCA, 4(22.22%) and 2(11.11%) patients in LCX respec-
tively. 6 (25%) had lesion in SVG graft.
In 20 (83.33%) patients, total 26 lesions in native vessels were
attempted. 2(7.69%) could not be opened because of CTO. 24 were
stented, had 9(34.61%) in LAD, 9(34.61%) in RCA and 6(25%) in LCX.
Total 23(88.46%) DES and 3(11.54%) BMS were used.
4(16.66%) underwent attempted PTCA to SVG graft. 3(75%) un-
derwent successful PTCA, all with BMS. During procedure, one
had graft perforation which was sealed with covered stent
All patients are following regularly in OPD. Mean follow up is
15.6 months. 5(23.80%) lost follow up. 6(28.57%) developed chest
pain who underwent stress thallium scan and all were negative.
3(14.28%) presented with ACS (2 USA,1 NSTMI), only 1 had instent
thrombosis.
Conclusion: Post CABG PTCA can be attempted in native vessel
and graft and has high success rate as in our institute
Can rotablation atherectomy bypass the bypass
surgery in ‘drug eluting stent’ era?
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Background: The patients with heavily calcified lesions, espe-
cially in LAD or LM are referred to the surgeons. When patients
were unwilling for CABG, Rotablation atherectomy (RA) used to
be popular for mechanical debulking in bare-metal stent era but
later it became less popular as it was technically demanding
and outcomes following PTCA were not promising. This study
was done to evaluate our institutional experience with RA and
followed by DES implantation in heavily calcified coronary
lesions.
Methods: From August, 2012 to July, 2014 we had 18 cases of
heavily calcified de novo lesions that underwent RA followed by
DES implantation. The database at base line and all follow-up
visits were analyzed.
Results: A total of 18 patients underwent RA for heavily calcified
coronary lesions followed by DES implantation during the study
period. Of them 60% were diabetics. Multivessel disease was seen
in 6 patients. The lesions that had RA were eLAD (13), LCx (3) and
RCA (2). Of them 30% were either balloon-non-crossable or non-
dilatable (1.25 mm balloon). Procedural success was 17/18 (94.4 %).
There were no procedure related MACE at 30 days. At mean
follow-up of 5.5 ± 1.35 months, 1 developed CRF and 1 needed
elective CABG.
Conclusion: RA followed by DES was safe with promising acute
and short term results in patients with heavily calcified coronary
lesions and bypass surgery could be avoided in almost all of them.
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Background: Since its introduction in 2012, Bioresorbable Vascular
Scaffolds (BVS) had shown promising results when used in spec-
ified coronary lesions. The experience in ‘Off-label’ indications is
limited.
Methods: We studied the technical feasibility, immediate and
short-term outcome of usage of BVS the ‘real-world’ cases
including off-label indications in our institute over the last 2 years.
We used 30 devices in 20 patients during this period. Standard
protocols were followed for the choice of hardware and dual an-
tiplatelet agents. The data is analyzed for lesion characteristics,
immediate results and 30-day follow-up.
Results: Of the 865 patients that had undergone PTCA during the
study period, BVS were implanted in 20 patients (4 females). The
mean age was 58 ±2.05 years. Of them 60%were diabetics and 65%
were smokers. The location of the lesions was LAD (16), RCA (10),
LCx/OM (3) or Ramus (1). The size of devices most frequently used
included 3x 28 mm (13) 2.5 x28 mm(6) and 3x 18 mm (5).In 2 cases
lesions were ostial and in 3 cases two stents with overlapping had
to be done due to long segment disease. Multi-lesional PTCA was
done in 5 cases. Of the 30 devices, four were used in 1 patient,
three in 1, two in 5 and one each in rest of them. Procedural
success was obtained in 19/20 (95%) procedures. One patient
developed acute thrombosis in BVS on day one and had responded
to balloon dilation and tirofiban infusion. There was no MACE at
30 day and 3 month follow-up. One patient at 5 month follow-up
developed angina and had angiographic restenosis. Re-PTCA with
DES was done. Patient was symptom-free at follow-up 3 months
later.
Conclusions: In this real-world experience in a single center, with
implantation of 30 BVS, the immediate results and short-term
outcomes were very promising. Off-label use had been equally
rewarding in our study.
Unprotected left main coronary artery stenting: A
single unit experience
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Background: Severe Unprotected LMCA disease, either isolated or
associated with other stenoses, is usually treated by CABG
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